Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.95 |
| ▸ | MEN1 | O00255 | 10/20 | 0.95 |
| ▸ | THRB | P10828 | 10/20 | 0.95 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.95 |
| ▸ | BLM | P54132 | 9/20 | 0.95 |
| ▸ | RECQL | P46063 | 8/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.95 |
| ▸ | MAPT | P10636 | 7/20 | 0.95 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.95 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.95 |
| ▸ | BRCA1 | P38398 | 6/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.95 |
| ▸ | HTT | P42858 | 5/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.95 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.95 |
| ▸ | STAT6 | P42226 | 4/20 | 0.95 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.95 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.95 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL18263941 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL1030848 | 1.00 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL28086230 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL23753547 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL4019285 | 0.99 | MEN1 (0.95) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL28183637 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL13858183 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL94408 | 0.99 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL8183120 | 0.98 | MEN1 (0.92) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL21184881 | 0.97 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059240-A1 | METHOD FOR PREPARATION OF MICELLAR HYBRID NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS AND COMPOSITIONS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-08 | — | — | US | claimed |
| EP-1313762-B1 | SUPPRESSOR GENE | LUDWIG INST CANCER RES (CH) | 2006-07-05 | — | — | EP | claimed |
| WO-2023121753-A1 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-29 | — | — | WO | disclosed |
| US-10646524-B2 | Modified oncolytic vaccinia viruses expressing a cytokine and a car-boxylesterase and methods of use thereof | SILLAJEN, INC. (KR) | 2020-05-12 | — | — | US | disclosed |
| US-20180271921-A1 | MODIFIED ONCOLYTIC VACCINIA VIRUSES EXPRESSING A CYTOKINE AND A CAR- BOXYLESTERASE AND METHODS OF USE THEREOF | SILLAJEN, INC. (KR) | 2018-09-27 | — | — | US | disclosed |
| WO-2017046037-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION AND THEIR USES | ONXEO (FR) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | ONXEO S.A. (FR) | 2017-03-16 | — | — | US | disclosed |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| WO-2016077858-A1 | BIOMARKERS OF DISEASE AND THEIR USE IN DISEASE DETECTION AND MANAGEMENT | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-05-26 | — | — | WO | disclosed |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-29 | — | — | US | disclosed |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-03-15 | — | — | US | disclosed |
| EP-1242438-A1 | CYTOTOXIC AGENTS COMPRISING MODIFIED DOXORUBICINS AND DAUNORUBICINS AND THEIR THERAPEUTIC USE | Immunogen, Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6423491-B1 | DETECTING PREFERENTIAL GASTROINTESTINAL CANCER IN HUMANS; OBTAIN SAMPLE OF GASTROINTESTINAL TISSUE, SCREEN NUCLELOTIDE SEQUENCES FOR PREFERENTIAL MUTATION, PRESENCE OF MUTATION INDICATES DISORDER | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2002-07-23 | — | — | US | disclosed |
| EP-1135485-A2 | PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION | Genentech, Inc. (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001049698-A1 | CYTOTOXIC AGENTS COMPRISING MODIFIED DOXORUBICINS AND DAUNORUBICINS AND THEIR THERAPEUTIC USE | IMMUNOGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2000032221-A2 | PROMOTION OR INHIBITION OF ANGIOGENESIS AND CARDIOVASCULARIZATION | GENENTECH, INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| US-5989869-A | CULTURING GENETICALLY ENGINEERED STREPTOMYCES IN WHICH GENE INVOLVED IN GLYCOSYLATION HAS BEEN DEACTIVATED | PHARMACIA & UPJOHN S.P.A. (IT) | 1999-11-23 | — | — | US | disclosed |
| EP-0915983-A1 | PROCESS FOR PREPARING DOXORUBICIN | Pharmacia & Upjohn S.p.A. (IT) | 1999-05-19 | — | — | EP | disclosed |
| US-5817321-A | ANTICANCER CHEMOTHERAPUTIC AGENT, POLYETHER BLOCK COPOLYMER | SUPRATEK PHARMA, INC. (CA) | 1998-10-06 | — | — | US | disclosed |
| WO-1998039458-A1 | PROCESS FOR PREPARING DOXORUBICIN | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | MPO, EXOSC9, CD63 | TOP2A 1164/4885MEN1 3260/4885THRB 4853/4885 |
| US-20160168151-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | TOP2A 2007/4885MEN1 4846/4885THRB 3639/4885 |
| US-20150031881-A1 | PYRAZOLO PYRIMIDINE DERIVATIVES AND METHODS OF USE THEREOF | DPYD, DHODH, DLD | TOP2A 2007/4885MEN1 4846/4885THRB 3639/4885 |
| US-20120065154-A1 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof | DPYD, DHODH, DLD | TOP2A 2007/4885MEN1 4846/4885THRB 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.